Thorsten Degenhardt

Dr. Thorsten Degenhardt provides technical and strategic leadership to the Mycovia Pharmaceuticals team and is responsible for all non-clinical development aspects of the company’s antifungal programs, including chemistry and manufacturing, pharmacology/toxicology, regulatory affairs and project management. Dr. Degenhardt previously worked at Viamet Pharmaceuticals for more than 7 years, where he directed and advanced the company’s development programs through the submission of INDs and beyond, including the recent successful completion of Phase 2b studies in recurrent vulvovaginal candidiasis and onychomycosis. He previously served in multiple leadership positions at Cempra (now Melinta Therapeutics) and BioStratum where he was responsible for all development aspects of their lead programs.

Dr. Degenhardt holds an MS in Biochemistry from the Technical University of Darmstadt and a PhD in pharmaceutical chemistry from Heidelberg University. He subsequently completed postdoctoral studies and worked as a Research Assistant Professor at the Department of Biochemistry at the University of South Carolina.